MCID: LCL006
MIFTS: 61

Localized Scleroderma

Categories: Bone diseases, Immune diseases, Nephrological diseases, Rare diseases, Respiratory diseases, Skin diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Localized Scleroderma

MalaCards integrated aliases for Localized Scleroderma:

Name: Localized Scleroderma 11 19 58 14 71 75
Morphea 11 19 53 71 75
Localized Fibrosing Scleroderma 19 58
Localised Scleroderma 11 16
Scleroderma, Circumscribed or Localised 11
Scleroderma, Circumscribed or Localized 11
Circumscribed Scleroderma 11
Scleroderma, Localized 19
Localised Morphoea 11
Localised Morphea 11
Localized Morphea 11

Characteristics:


Prevelance:

1-9/100000 (Europe) 58

Age Of Onset:

All ages 58

Classifications:

Orphanet: 58  
Rare skin diseases


Summaries for Localized Scleroderma

GARD: 19 Localized scleroderma is characterized by thickening of the skin from excessive collagen deposits. Collagen is a protein normally present in our skin that provides structural support. However, when too much collagen is made, the skin becomes stiff and hard. Localized types of scleroderma are those limited to the skin and related tissues and, in some cases, the muscle below. Internal organs are not affected by Localized scleroderma, and Localized scleroderma can never progress to the systemic form of the disease. Often, localized conditions improve or go away on their own over time, but the skin changes and damage that occur when the disease is active can be permanent. For some people, Localized scleroderma is serious and disabling. There are two generally recognized types of Localized scleroderma: morphea and linear.

MalaCards based summary: Localized Scleroderma, also known as morphea, is related to facial hemiatrophy and scleroderma, familial progressive, and has symptoms including pruritus and exanthema. An important gene associated with Localized Scleroderma is MMP1 (Matrix Metallopeptidase 1), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Lidocaine and Anti-Arrhythmia Agents have been mentioned in the context of this disorder. Affiliated tissues include skin, lung and skeletal muscle, and related phenotypes are thickened skin and arthralgia

Orphanet: 58 Localized scleroderma is the skin localized form of scleroderma (see this term) characterized by fibrosis of the skin causing cutaneous plaques or strips.

Wikipedia: 75 Morphea is a form of scleroderma that involves isolated patches of hardened skin on the face, hands, and... more...

Related Diseases for Localized Scleroderma

Diseases in the Systemic Scleroderma family:

Scleroderma, Familial Progressive Localized Scleroderma

Diseases related to Localized Scleroderma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 910)
# Related Disease Score Top Affiliating Genes
1 facial hemiatrophy 32.0 SNRNP70 EXOSC10
2 scleroderma, familial progressive 31.4 TOP1 FBN1 COL1A2 CCN2
3 fasciitis 30.6 TNF MMP1 IL6 CD34
4 skin atrophy 30.5 TNF IL4 H2AC18
5 autoimmune disease 30.4 TNF IL6 IL4 IL2RA IL13
6 crest syndrome 30.4 TOP1 SNRNP70 H2AC18 EXOSC10
7 diffuse scleroderma 30.4 TSSK1B TOP1 SNRNP70 EXOSC10 CCN2
8 uveitis 30.3 TNF IL6 IL4 IL2RA
9 basal cell carcinoma 30.3 TNF MMP1 IL6 H2AC18 CD34
10 purpura 30.2 TNF IL6 IL4
11 granuloma annulare 30.2 TNF CD8A CD4
12 thyroiditis 30.2 TNF IL6 IL4
13 scleredema adultorum 30.1 MMP1 FBN1 DCN CD8A
14 dermatitis 30.0 TNF IL6 IL4 IL13
15 esophagitis 30.0 TNF IL6 IL4 IL13
16 covid-19 30.0 TNF IL6 IL4 IL2RA
17 lichen planus 30.0 TNF IL6 IL4
18 folliculitis 30.0 TNF IL4 CD4
19 juvenile rheumatoid arthritis 29.9 TNF IL6 IL2RA CD4
20 schistosomiasis 29.9 TNF IL4 IL13
21 collagen disease 29.9 SNRNP70 IL6 H2AC18 FBN1 EXOSC10 DCN
22 panniculitis 29.9 IL2RA CD8A CD4
23 adult syndrome 29.9 TNF IL6 H2AC18
24 vitiligo-associated multiple autoimmune disease susceptibility 1 29.9 TNF CD8A CD4
25 rubella 29.9 TNF IL6 IL4 IL2RA
26 mixed connective tissue disease 29.9 TNF SNRNP70 IL6
27 osteomyelitis 29.9 TNF MMP1 IL6 IL4 CTSK
28 granulomatous dermatitis 29.9 TNF CD8A CD4
29 marfan syndrome 29.9 MMP1 LOX FBN1 DCN COL1A2
30 systemic scleroderma 29.9 TSSK1B TOP1 TNF SNRNP70 IL6 IL4
31 hashimoto thyroiditis 29.9 IL4 IL2RA H2AC18 CD8A CD4
32 septic arthritis 29.8 TNF IL6 CD4
33 henoch-schoenlein purpura 29.8 TNF IL6 CD4
34 dyskinesia of esophagus 29.8 TOP1 SNRNP70 IL13 EXOSC10
35 central nervous system vasculitis 29.8 TNF IL6 CD8A CD4
36 oral submucous fibrosis 29.8 TNF LOX COL1A2
37 chronic ulcer of skin 29.8 TNF MMP1 IL6
38 xerophthalmia 29.8 TNF CD8A CD4
39 childhood type dermatomyositis 29.8 TNF SNRNP70 EXOSC10 CD4
40 inflammatory bowel disease 1 29.8 TNF IL6 H2AC18
41 toxoplasmosis 29.7 TNF IL6 IL4
42 skin carcinoma 29.7 TNF H2AC18 CD8A CD4
43 aortic aneurysm 29.7 TNF MMP1 LOX IL6 FBN1
44 osteoarthritis 29.7 TNF MMP1 IL6 DCN CTSK
45 telangiectasis 29.7 TOP1 TNF SNRNP70 H2AC18 FBN1 EXOSC10
46 spondyloarthropathy 1 29.7 TNF IL6 CD8A CD4
47 bronchiolitis obliterans 29.7 TNF IL6 IL13
48 proteasome-associated autoinflammatory syndrome 1 29.7 TNF IL6 IL4 IL13
49 lung disease 29.7 TNF IL6 IL13 H2AC18 CCN2
50 alopecia areata 29.7 TNF IL6 IL4 IL2RA IL13

Comorbidity relations with Localized Scleroderma via Phenotypic Disease Network (PDN):


Systemic Scleroderma Vulva Cancer

Graphical network of the top 20 diseases related to Localized Scleroderma:



Diseases related to Localized Scleroderma

Symptoms & Phenotypes for Localized Scleroderma

Human phenotypes related to Localized Scleroderma:

58 30 (show top 50) (show all 57)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 thickened skin 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0001072
2 arthralgia 58 30 Frequent (33%) Frequent (79-30%)
HP:0002829
3 stiff skin 58 30 Frequent (33%) Frequent (79-30%)
HP:0030053
4 cutaneous sclerotic plaque 58 30 Frequent (33%) Frequent (79-30%)
HP:0031359
5 dental malocclusion 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0000689
6 arthritis 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001369
7 flexion contracture 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001371
8 gastroesophageal reflux 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002020
9 myopathy 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0003198
10 abnormality of vision 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0000504
11 uveitis 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0000554
12 hypopigmented skin patches 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001053
13 migraine 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002076
14 erythema 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0010783
15 infra-orbital crease 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0100876
16 upper limb asymmetry 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0100560
17 fasciitis 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0100537
18 abnormality of upper lip 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0000177
19 patchy alopecia 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002232
20 hyperpigmentation of the skin 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0000953
21 erythematous plaque 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0025474
22 hemifacial atrophy 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0011331
23 sclerosis of finger phalanx 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0100899
24 progressive loss of facial adipose tissue 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0009019
25 short dental root 30 Occasional (7.5%) HP:0006336
26 abnormal cheek morphology 30 Occasional (7.5%) HP:0004426
27 abnormal facial skeleton morphology 30 Occasional (7.5%) HP:0011821
28 skeletal muscle atrophy 58 30 Very rare (1%) Very rare (<4-1%)
HP:0003202
29 hashimoto thyroiditis 58 30 Very rare (1%) Very rare (<4-1%)
HP:0000872
30 vitiligo 58 30 Very rare (1%) Very rare (<4-1%)
HP:0001045
31 arrhythmia 58 30 Very rare (1%) Very rare (<4-1%)
HP:0011675
32 deeply set eye 58 30 Very rare (1%) Very rare (<4-1%)
HP:0000490
33 proptosis 58 30 Very rare (1%) Very rare (<4-1%)
HP:0000520
34 stroke 58 30 Very rare (1%) Very rare (<4-1%)
HP:0001297
35 abnormality of the kidney 58 30 Very rare (1%) Very rare (<4-1%)
HP:0000077
36 vasculitis 58 30 Very rare (1%) Very rare (<4-1%)
HP:0002633
37 abnormality of the nose 58 30 Very rare (1%) Very rare (<4-1%)
HP:0000366
38 abnormal blistering of the skin 58 30 Very rare (1%) Very rare (<4-1%)
HP:0008066
39 skin erosion 58 30 Very rare (1%) Very rare (<4-1%)
HP:0200041
40 raynaud phenomenon 58 30 Very rare (1%) Very rare (<4-1%)
HP:0030880
41 esophagitis 58 30 Very rare (1%) Very rare (<4-1%)
HP:0100633
42 focal impaired awareness seizure 58 30 Very rare (1%) Very rare (<4-1%)
HP:0002384
43 abnormality on pulmonary function testing 58 30 Very rare (1%) Very rare (<4-1%)
HP:0030878
44 seizure 58 Very rare (<4-1%)
45 abnormality of the dentition 58 Occasional (29-5%)
46 abnormality of the cardiovascular system 58 Very rare (<4-1%)
47 autoimmunity 58 Occasional (29-5%)
48 facial asymmetry 58 Occasional (29-5%)
49 headache 58 Occasional (29-5%)
50 abnormality of the nervous system 58 Very rare (<4-1%)

UMLS symptoms related to Localized Scleroderma:


pruritus; exanthema

GenomeRNAi Phenotypes related to Localized Scleroderma according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 10.13 CCN2 CD34 CD4 CD8A COL1A2 CTSK
2 no effect GR00402-S-2 10.13 CCN2 CD34 CD4 COL1A2 DCN H2AC18

MGI Mouse Phenotypes related to Localized Scleroderma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.3 CCN2 CD34 CD4 COL1A2 CTSK DCN
2 cellular MP:0005384 10.18 CCN2 CD34 CD4 CD8A COL1A2 CTSK
3 endocrine/exocrine gland MP:0005379 10.17 CCN2 CD4 CD8A CTSK DCN FBN1
4 immune system MP:0005387 10.17 CD34 CD4 CD8A COL1A2 CTSK DCN
5 digestive/alimentary MP:0005381 10.06 CCN2 CD4 CTSK DCN IL13 IL2RA
6 respiratory system MP:0005388 9.96 CCN2 CTSK DCN FBN1 IL13 IL2RA
7 skeleton MP:0005390 9.9 CCN2 COL1A2 CTSK DCN FBN1 IL13
8 hematopoietic system MP:0005397 9.77 CD34 CD4 CD8A COL1A2 CTSK DCN
9 integument MP:0010771 9.4 CCN2 CD34 CD4 CD8A COL1A2 DCN

Drugs & Therapeutics for Localized Scleroderma

Drugs for Localized Scleroderma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 146)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
2 Anti-Arrhythmia Agents Phase 4
3 Sodium Channel Blockers Phase 4
4 Anesthetics, Local Phase 4
5 Diuretics, Potassium Sparing Phase 4
6
Macitentan Approved Phase 2, Phase 3 441798-33-0 16004692
7
Sildenafil Approved, Investigational Phase 3 139755-83-2, 171599-83-0 5212 135398744
8
Sodium citrate Approved, Investigational Phase 3 68-04-2 23431961
9
Tadalafil Approved, Investigational Phase 3 171596-29-5 110635
10
Acetylcholine Approved, Investigational Phase 3 51-84-3 187
11
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
12
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
13
Prednisolone acetate Approved, Vet_approved Phase 3 52-21-1
14
Prednisolone Approved, Vet_approved Phase 3 50-24-8 4894 5755
15
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5 1875
16
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 4159 6741
17
Lenograstim Approved, Investigational Phase 3 135968-09-1
18
Mycophenolic acid Approved, Investigational Phase 3 24280-93-1 446541
19
Coenzyme M Approved, Investigational Phase 3 3375-50-6 598 23662354
20
Citric acid Approved, Nutraceutical, Vet_approved Phase 3 77-92-9 311
21
Prednisolone hemisuccinate Experimental Phase 3 2920-86-7 4897
22 Endothelin A Receptor Antagonists Phase 2, Phase 3
23 Pharmaceutical Solutions Phase 3
24 Anesthetics Phase 2, Phase 3
25 Alkylating Agents Phase 3
26 Antineoplastic Agents, Alkylating Phase 3
27 Anticoagulants Phase 3
28 Phosphodiesterase Inhibitors Phase 3
29 Phosphodiesterase 5 Inhibitors Phase 3
30 Vasodilator Agents Phase 3
31 Citrate Phase 3
32 Calcium, Dietary Phase 3
33 Neurotransmitter Agents Phase 3
34 Insulin, Globin Zinc Phase 3
35
Insulin Phase 3
36
abobotulinumtoxinA Phase 3
37 Botulinum Toxins, Type A Phase 3
38 Botulinum Toxins Phase 3
39 Cholinergic Agents Phase 3
40 Chelating Agents Phase 3
41 Immunosuppressive Agents Phase 3
42
Methylprednisolone Acetate Phase 3 584547
43 Antilymphocyte Serum Phase 3
44 Thymoglobulin Phase 3
45
Calcium Nutraceutical Phase 3 7440-70-2 271
46
Rituximab Approved Phase 2 174722-31-7
47
Abatacept Approved Phase 1, Phase 2 332348-12-6
48
Epoprostenol Approved Phase 2 61849-14-7, 35121-78-9 5282411
49
Treprostinil Approved, Investigational Phase 2 81846-19-7 6918140
50
Dasatinib Approved, Investigational Phase 1, Phase 2 302962-49-8 3062316

Interventional clinical trials:

(show top 50) (show all 117)
# Name Status NCT ID Phase Drugs
1 Safety and Efficacy of Vaccination Against Influenza in Patients With Scleroderma Unknown status NCT01002508 Phase 4
2 The Use of Local Anesthetic in Intralesional Corticosteroid Injections; A Randomized, Double Blind Controlled Trial Completed NCT03630198 Phase 4 Corticosteroid with lidocaine;Corticosteroid with normal saline
3 A Phase IV, Single-arm, Open-label Clinical Trial to Evaluate the Efficacy and Safety of PLACENTEX ® Polydeoxyribonucleotide i.m. in Patients With Fibrotic and Atrophic Cutaneous Lesions in Scleroderma Diseases Terminated NCT03388255 Phase 4 Polydeoxyribonucleotides
4 CompRehensive Phenotypic Characterization of Patients With Scleroderma-Associated Interstitial Lung DiseasE and Pulmonary Hypertension (PH): The CRuSADE PH Study Unknown status NCT03726398 Phase 2, Phase 3 Opsumit 10 Mg Tablet
5 Evaluation of the Efficacy and Safety of the Imiquimod 5% Topical Cream in Plaque Morphea: A Prospective, Multiple Baseline, Open Label Pilot Study Completed NCT00147771 Phase 3 Imiquimod 5% cream
6 Effectiveness and Safety of Lidocaine for Scleroderma. Randomized Double-Blind Clinical Trial Completed NCT00740285 Phase 2, Phase 3 Lidocaine 2% without vessel constrictor
7 High Dose Cyclophosphamide for Treatment of Systemic Sclerosis (Scleroderma) Completed NCT00501995 Phase 3 IV Cyclophosphamide
8 Cyclophosphamide Versus Placebo in Scleroderma Lung Study Completed NCT00004563 Phase 3 Cyclophosphamide;Placebo
9 A Randomized Control Trial to Assess the Efficacy of Tadalafil in Raynaud's Phenomenon in Scleroderma: A Double Blind, Parallel Group, Multicentric Study Completed NCT01117298 Phase 3 Tadalafil;Placebo
10 A Randomized, Double-Blinded, Placebo-Controlled Clinical Trial Assessing the Therapeutic Efficacy of Botulinum Toxin In Treating Scleroderma-Associated Raynaud's Syndrome Completed NCT02165111 Phase 3 Onabotulinumtoxin A;sterile saline solution
11 Effect of Sildenafil on the Microcirculatory Blood Flow and on the Endothelial Progenitor Cells in Patients With Systemic Sclerosis: a Randomized, Double-blind, Placebo-controlled Clinical Trial Completed NCT01347008 Phase 3 Sildenafil citrate;Placebo (Sugar pill)
12 Evaluation of the Efficacy of Sildenafil on Time to Healing in Patients With Scleroderma and Ischaemic Digital Ulcers: a Prospective, Longitudinal, Randomized, Comparative, Double-blind, 2-parallel-arm, Placebo-controlled Study Completed NCT01295736 Phase 3 Sildenafil;placebo
13 Upfront Autologous Hematopoietic Stem Cell Transplantation Versus Immunosuppressive Medication in Early Diffuse Cutaneous Systemic Sclerosis: an International Multicentre, Open-label, Randomized Con-trolled Trial Recruiting NCT04464434 Phase 3
14 Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells - A Randomized, Double-Blind, Placebo-Controlled Study - The STAR-II Trial Not yet recruiting NCT05148598 Phase 3
15 Evaluation of the Efficacy and Safety of Imiquimod 5% Cream in Plaque-type Morphea: A Pilot, Prospective Open-label Study Withdrawn NCT00230373 Phase 3 imiquimod 5% cream (Aldara)
16 Pilot Study Evaluating the Efficacy of a Topical PDE4 Inhibitor for Morphea Completed NCT03351114 Phase 2 Crisaborole
17 A Protocol Based Treatment for Debilitating Fibrosing Skin Disorders With (Anti-CD 20), Rituximab, Evaluating Safety and Efficacy Completed NCT00936546 Phase 2 Rituximab
18 Phase II Randomized Double Blind Clinical Trial of'Imatinib Mesylate STI571 (Glivec®) Versus Placebo in Patients With Severe Cutaneous Scleroderma or Systemic Sclerosis With Severe Cutaneous Involvement. Completed NCT00479934 Phase 2 imatinib mesylate
19 The Effectiveness of UVB Irradiation in the Treatment of Skin Conditions With Altered Dermal Matrix: An Open Pilot Study Completed NCT00129428 Phase 1, Phase 2
20 A Phase II, Single Centre, Randomised, Placebo-controlled, 3-part Trial to Assess the Safety, Tolerability and Efficacy of Zibotentan in Patients With Renal Disease Secondary to Scleroderma Completed NCT02047708 Phase 2 Zibotentan
21 A Pilot Study to Evaluate the Safety and Efficacy of Abatacept in Patients With Systemic Sclerosis Completed NCT00442611 Phase 1, Phase 2 Abatacept;Placebo
22 DISTOL-1: Digital Ischemic Lesions in Scleroderma Treated With Oral Treprostinil Diethanolamine: A Randomized, Double-blind, Placebo-controlled, Multicenter Study Completed NCT00775463 Phase 2 treprostinil diethanolamine;placebo
23 An Open Label Study to Evaluate the Safety of Dasatinib in the Treatment of Scleroderma Pulmonary Interstitial Fibrosis Completed NCT00764309 Phase 1, Phase 2 dasatinib
24 Multicenter Phase II Trial of Oral Type I Bovine Collagen in Scleroderma Completed NCT00005675 Phase 2 Oral bovine type I collagen;Placebo
25 Psychosocial Interventions for Scleroderma Completed NCT00007267 Phase 2
26 Mycophenolate vs. Oral Cyclophosphamide in Scleroderma Interstitial Lung Disease (Scleroderma Lung Study II) Completed NCT00883129 Phase 2 Mycophenolate mofetil;Cyclophosphamide;Placebo
27 Trial of High Dose Cyclophosphamide and Rabbit Antithymocyte Globulin (rATG) With Hematopoietic Stem Cell Support in Patients With Systemic Scleroderma: A Randomized Trial Completed NCT00278525 Phase 2 standard of care
28 Assessing and Comparing the Effect of Diltiazem Gel Versus Nitroglycerin Ointment in Healing Process of Scleroderma Digital Ulcers. Completed NCT02801305 Phase 2 Diltiazem Gel 2%;Nitroglycerin Ointment 2%;Vaseline
29 Effect of Bosentan in the Course of Scleroderma Renal Crisis Completed NCT01241383 Phase 2 Bosentan
30 Randomized, Double-Blind, Placebo-Controlled Trial if IL1-TRAP, Rilonacept, in Systemic Sclerosis -A Phase I/II Biomarker Trial Completed NCT01538719 Phase 1, Phase 2 Rilonacept
31 A Multi-center Randomized, Double Blind, Placebo-controlled, Pilot Study to Assess the Efficacy and Safety of Riociguat in Scleroderma - Associated Digital Ulcers Completed NCT02915835 Phase 2 Riociguat;Placebo
32 Treatment of Refractory Sever Systemic Scleroderma by Injection of Allogeneic Mesenchymal Stem Cells Completed NCT02213705 Phase 1, Phase 2
33 A Randomized, Placebo-controlled Phase IIa Clinical Trial to Evaluate the Efficacy and Safety of Subcutaneous Dupilumab in Localized Scleroderma Recruiting NCT04200755 Phase 2 Dupilumab 300Mg Solution for Injection
34 A Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Ifetroban in Patients With Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension (SSc-PAH) Recruiting NCT02682511 Phase 2 Oral Ifetroban;Oral Placebo
35 Sildenafil for Early Pulmonary Vascular Disease in Scleroderma Recruiting NCT04797286 Phase 2 Sildenafil
36 A Phase 2 Open-Label Pilot Study of the Safety and Tolerability of Ixazomib Administered Orally to Patients With Scleroderma-Related Interstitial Lung Disease Recruiting NCT04837131 Phase 2 Ixazomib
37 A Phase II, Randomised, Double Blind, Placebo-controlled Study of the Pharmacokinetics, Pharmacodynamic Effects, and Safety, of Oral FT011 in Participants With Diffuse Systemic Sclerosis Active, not recruiting NCT04647890 Phase 2 FT011;Placebo
38 Scleroderma Lung Study III (SLS III): Combining the Anti-fibrotic Effects of Pirfenidone (PFD) With Mycophenolate (MMF) for Treating Scleroderma-related Interstitial Lung Disease Active, not recruiting NCT03221257 Phase 2 Pirfenidone (PFD);Placebo (Plac);Mycophenolate Mofetil (MMF)
39 A Phase 1/2 Study of a Combination of FCX-013 (Genetically-Modified Autologous Human Dermal Fibroblasts) Plus Veledimex for the Treatment of Moderate to Severe Localized Scleroderma (Morphea) Terminated NCT03740724 Phase 1, Phase 2 veledimex
40 Placebo Controlled Trial of Bosentan vs Placebo in NYHA Class I/II Scleroderma Patients With Exercise Induced Pulmonary Hypertension Terminated NCT00377455 Phase 2 Bosentan;Placebo
41 A Phase 2, Proof-Of-Concept, Multicenter, Randomized, Double-Blind, Placebo- Controlled, Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Pomalidomide (CC-4047) in Subjects With Systemic Sclerosis With Interstitial Lung Disease Terminated NCT01559129 Phase 2 Pomalidomide (CC-4047);Placebo
42 A Proof of Concept Trial of Gleevec (Imatinib) in Active Diffuse Scleroderma Terminated NCT01545427 Phase 2 Imatinib mesylate
43 A Pilot Study to Assess the Safety and Efficacy of Sarilumab in Halting Progression of Morphea Withdrawn NCT03679845 Phase 1, Phase 2 Sarilumab
44 Safety & Suitability of Dabigatran to Inhibit Thrombin in Scleroderma Completed NCT02426229 Phase 1 dabigatran etexilate
45 A Phase 1, Randomized, Double-blind, Placebo-controlled Study of the Safety and Tolerability of MEDI-551 in Scleroderma Completed NCT00946699 Phase 1
46 A Phase 1 Multicenter, Open-label Study to Evaluate the Safety and Tolerability of Single and Multiple Intravenous Doses of MEDI-546, a Fully Human Monoclonal Antibody Directed Against Subunit 1 of the Type I Interferon Receptor, in Adult Subjects With Scleroderma Completed NCT00930683 Phase 1 MEDI-546
47 Comparative Effectiveness Trial of Topical Calcipotriene, Clobetasol, and Tacrolimus in the Treatment of Pediatric Plaque Morphea Withdrawn NCT02680717 Phase 1 Clobetasol;Calcipotriene;Tacrolimus
48 Fractional Carbon Dioxide Laser Versus UVA1 Phototherapy for Treatment of Localized Scleroderma: A Clinical & Immunohistochemical Comparative Study Unknown status NCT02002897
49 Adult-onset Generalized Morphea : A Retrospective Multicenter Study Unknown status NCT04264728
50 Pilot Study of descriPtion of cicatriSation Rates of Digital Ulcers in Systemic scleroDerma Unknown status NCT04319120

Search NIH Clinical Center for Localized Scleroderma

Genetic Tests for Localized Scleroderma

Anatomical Context for Localized Scleroderma

Organs/tissues related to Localized Scleroderma:

MalaCards : Skin, Lung, Skeletal Muscle, T Cells, Kidney, Eye, Endothelial

Publications for Localized Scleroderma

Articles related to Localized Scleroderma:

(show top 50) (show all 2383)
# Title Authors PMID Year
1
Autoantibodies against matrix metalloproteinase-1 in patients with localized scleroderma. 53 62
18565735 2008
2
Differential expression of decorin in localized scleroderma following ultraviolet-A1 irradiation. 53 62
17184878 2007
3
Collagen degradation products and proinflammatory cytokines in systemic and localized scleroderma. 53 62
17448296 2007
4
Suggested mechanisms of action of UVA phototherapy in morphea: a molecular study. 53 62
15030594 2004
5
Induction of interstitial collagenase (MMP-1) by UVA-1 phototherapy in morphea fibroblasts. 53 62
9357412 1997
6
Clinical significance of serum levels of soluble interleukin-2 receptor in patients with localized scleroderma. 53 62
8736323 1996
7
Increased expression of lysyl oxidase in skin with scleroderma. 53 62
8555021 1995
8
Decreased expression of the human progenitor cell antigen (CD34) in morphea. 53 62
8599452 1995
9
Stimulated expression of decorin and the decorin gene in fibroblasts cultured from patients with localized scleroderma. 53 62
7625849 1995
10
Serum levels of soluble interleukin-2 receptor. A marker of disease activity in localized scleroderma. 53 62
8003062 1994
11
Immunocytochemical localization and serologic detection of transforming growth factor beta 1. Association with type I procollagen and inflammatory cell markers in diffuse and limited systemic sclerosis, morphea, and Raynaud's phenomenon. 53 62
7510487 1994
12
Serum levels of soluble interleukin-2 receptor in systemic and circumscribed scleroderma. 53 62
1392125 1992
13
Expression of osteonectin, decorin, and transforming growth factor-beta 1 genes in fibroblasts cultured from patients with systemic sclerosis and morphea. 53 62
2023219 1991
14
[The diagnostic importance of research on the lysyl oxidase activity in children with circumscribed scleroderma]. 53 62
1976287 1990
15
Autoimmune conditions and pancreatic cancer risk in older American adults. 62
36059225 2023
16
Clinical and therapeutic course in head variants of linear morphea in adults: a retrospective review. 62
36456759 2022
17
Durvalumab-associated generalized morphea with overlapping vitiligo. 62
36407485 2022
18
Morphea disease activity during pregnancy: A case series. 62
36093764 2022
19
Tocilizumab for refractory morphea in adults: A case series. 62
36353292 2022
20
Linear morphea following Blaschko's line with epidermal downmodulation of friend leukemia integration 1 transcription factor. 62
35543915 2022
21
Narrow-band reflectance spectrophotometry and infrared thermography for assessment of skin lesions in localized scleroderma. 62
35925826 2022
22
Skin fibrosis associated with keloid, scleroderma and Jorge Lobo's disease (lacaziosis): An immuno-histochemical study. 62
36183172 2022
23
Fat Grafting for the Treatment of Localized Scleroderma: Confusion in the Current Clinical Practice. 62
36075042 2022
24
Clinical, epidemiological, trichoscopic and histopathological features of linear morphea on the scalp. 62
35694874 2022
25
Sclerosing tenosynovitis in a patient with pan-sclerotic morphea. 62
35671975 2022
26
The value of dermoscopy and high-frequency ultrasound in staging morphea. 62
36420557 2022
27
JAAD Game Changers∗: Inflammatory arthritis in pediatric patients with morphea. 62
35934212 2022
28
Tocilizumab for Corticosteroid-Refractory Immune Checkpoint Inhibitor-Induced Generalized Morphea. 62
36449277 2022
29
Rare presentation of calcification associated with long-standing linear morphea. 62
36416615 2022
30
Circumscribed Morphea of the Scalp: An Entity to Be Considered in the Differential Diagnosis of Cicatricial Alopecia. 62
36407637 2022
31
Prevalence and Incidence of Localized Scleroderma: A Qualitative Systematic Review. 62
36225142 2022
32
Juvenile localized scleroderma: A single-centre experience from India. 62
36413107 2022
33
Clinical and laboratory characterization of patients with localized scleroderma and response to UVA-1 phototherapy: In vivo and in vitro skin models. 62
35324032 2022
34
The co-occurrence of segmental vitiligo and linear morphea in a pediatric patient and a review of the literature. 62
36379693 2022
35
A case of anti-RNA polymerase III antibody-positive systemic sclerosis with generalized morphea-like lesions correlated with elevation of peripheral eosinophil counts. 62
35751638 2022
36
Gastrointestinal involvement in systemic sclerosis: An updated review. 62
36397401 2022
37
Tumor necrosis factor-α inhibitor-induced morphea and psoriasiform dermatitis in a pediatric patient with Crohn's disease. 62
36385392 2022
38
Linear morphea with overlying lichen sclerosus and calcinosis cutis associated with juvenile dermatomyositis. 62
36384242 2022
39
Bullous lichen sclerosus-generalized morphea overlap syndrome improved by tofacitinib. 62
36254686 2022
40
Evaluation of risk in chronic cutaneous inflammatory conditions for malignant transformation. 62
36251409 2022
41
Efficacy and Safety of Ablative Fractional Laser-Assisted Delivery of Methotrexate in Adults with Localized Scleroderma: A Randomized and Controlled Clinical Trial. 62
36365080 2022
42
Serum Levels of Selected IL-1 Family Cytokines in Patients with Morphea. 62
36362603 2022
43
Indurated plaques on the back: distinguishing stiff skin syndrome from scleredema and morphea. 62
34411278 2022
44
Concentrations of metalloproteinase-1 in patients with morphea treated with phototherapy: a preliminary study. 62
36457686 2022
45
Fat transplantation induces dermal adipose regeneration and reverses skin fibrosis through dedifferentiation and redifferentiation of adipocytes. 62
36210466 2022
46
Adipose Tissue Grafting for the Treatment of Morphea En Coup De Sabre: A Simple Filler or an Emerging Cellular Therapy? 62
36407158 2022
47
Morphea After Liposuction Ultrasonography. 62
35023212 2022
48
Leg ulcers in morphea plaques. 62
36075870 2022
49
Adipose-derived stem cells attenuate skin fibrosis and improve fat retention of localized scleroderma mouse model. 62
36206077 2022
50
Atypical Localized Scleroderma Development During Nivolumab Therapy for Metastatic Lung Adenocarcinoma. 62
36446107 2022

Variations for Localized Scleroderma

Expression for Localized Scleroderma

Search GEO for disease gene expression data for Localized Scleroderma.

Pathways for Localized Scleroderma

Pathways related to Localized Scleroderma according to GeneCards Suite gene sharing:

(show all 42)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.94 CD34 CD4 CD8A COL1A2 CTSK IL13
2
Show member pathways
13.79 CCN2 CD4 COL1A2 FBN1 IL13 IL2RA
3
Show member pathways
13.38 TNF IL6 IL4 IL2RA IL13 CD4
4
Show member pathways
13.27 TNF IL6 IL4 IL2RA IL13 CD4
5
Show member pathways
13.27 CD4 COL1A2 IL13 IL2RA IL4 IL6
6
Show member pathways
12.7 MMP1 LOX FBN1 DCN CTSK COL1A2
7
Show member pathways
12.62 CCN2 IL13 IL2RA IL4 IL6 TNF
8 12.55 TNF IL4 IL2RA CD8A CD34
9
Show member pathways
12.13 TNF IL4 CD8A CD4
10 12.09 TNF IL6 IL4 IL13
11
Show member pathways
11.95 IL4 IL2RA CD8A CD4
12 11.85 TNF IL4 IL2RA IL13
13 11.83 TNF MMP1 IL6 IL4 IL13 COL1A2
14
Show member pathways
11.82 IL6 IL4 CD4
15 11.76 COL1A2 CD4 CD34
16 11.75 MMP1 IL6 IL4 IL13
17
Show member pathways
11.74 IL6 CD8A CD4
18 11.7 TNF IL6 IL4
19 11.7 COL1A2 IL4 IL6 MMP1
20 11.69 CD4 IL2RA IL4 IL6
21
Show member pathways
11.67 TNF IL4 IL2RA
22 11.67 TNF IL6 CD8A CD4 CD34
23
Show member pathways
11.64 TNF MMP1 IL6
24
Show member pathways
11.6 TNF IL6 IL4 IL13
25 11.57 TNF IL6 IL4 IL13 CCN2
26 11.56 TNF IL6 IL4 IL2RA CD8A CD4
27 11.53 TNF IL4 IL2RA CD4
28 11.51 TNF MMP1 IL6 FBN1 DCN COL1A2
29 11.46 IL4 IL2RA IL13 CD4
30 11.32 IL4 IL2RA COL1A2
31 11.32 MMP1 IL6 DCN COL1A2
32 11.27 TNF MMP1 IL6
33 11.26 IL13 IL4 IL6 TNF
34 11.25 TNF IL6 CCN2
35 11.21 IL2RA IL13 CD4
36 11.17 TNF IL6 IL4 IL13
37 11.12 CD4 IL13 IL4 IL6 TNF
38 11.07 TNF IL4 IL2RA IL13 CD8A CD4
39 10.96 TNF IL6 IL4 IL13 FBN1 COL1A2
40 10.79 IL6 IL4 IL13
41 10.68 IL6 IL2RA
42
Show member pathways
10.35 TNF IL6

GO Terms for Localized Scleroderma

Cellular components related to Localized Scleroderma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular matrix GO:0031012 9.81 MMP1 LOX FBN1 COL1A2 CCN2
2 external side of plasma membrane GO:0009897 9.8 TNF IL2RA IL13 CTSK CD8A CD4
3 extracellular region GO:0005576 9.74 CCN2 CD34 CD8A COL1A2 CTSK DCN

Biological processes related to Localized Scleroderma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.76 IL13 IL4 IL6 TNF
2 microglial cell activation GO:0001774 9.73 TNF IL4 IL13
3 positive regulation of mononuclear cell migration GO:0071677 9.71 TNF IL4
4 negative regulation of complement-dependent cytotoxicity GO:1903660 9.62 IL4 IL13
5 positive regulation of interleukin-10 production GO:0032733 9.56 IL6 IL4 IL13 CD34
6 connective tissue development GO:0061448 9.54 LOX CCN2
7 immune response GO:0006955 9.47 TNF IL6 IL4 IL2RA IL13 CTSK

Sources for Localized Scleroderma

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....